Selected Engagaements
Navigating complex transactions and architecting sustainable growth across global markets
At Evolution GGP, we don’t just offer advice; we deliver executable blueprints. Every engagement is a partnership designed to solve high-stakes challenges—whether that involves stabilizing operations during rapid scaling, navigating the complexities of global market entry, or preparing an organization for a definitive liquidity event.
The following case studies represent a cross-section of our work as Business Architects. These select engagements highlight our "practitioner-first" approach, where senior-level C-suite experience meets hands-on execution. From life sciences to advanced manufacturing, we bridge the gap between strategic intent and realized value, ensuring our clients are equipped to handle their most pivotal corporate milestones.
Strategic Impact in Action - Sample Engagements
-
Take-Private Strategy and Global Asset Divestiture
The Challenge: A legacy NASDAQ-listed medical imaging pioneer faced a depressed valuation and required a total reorganization to unlock the value of its MIT-developed IP portfolio.
The Architecture: As part of a private equity-backed team, Evolution GGP architected a strategy to identify non-core business lines and find qualified international buyers to de-lever the balance sheet.
The Outcome: Successfully negotiated a $128M divestiture to a global industrial consortium and led the post-acquisition integration to pivot the technology for security and industrial manufacturing.
-
Establishing a Cross-Border Licensing for Nanoparticle Drug Delivery
The Challenge: A UK specialty biopharmaceutical company sought to monetize its nanoparticle drug delivery platform in verticals outside its core oncology focus.
The Architecture: Evolution GGP developed a multi-vertical international strategy and acted as the U.S. representative to identify and negotiate licensing deals with Asian partners.
The Outcome: Secured two major partnerships—one for livestock vaccine delivery and another for high-efficacy cosmetics—structured with upfront fees and long-term royalties.
-
Establishing a $15M Shenzhen-Based MedTech Joint VentureThe Challenge: A U.S. MedTech firm needed to establish a footprint in China, navigate NMPA registration, and set up regional manufacturing for its ML-driven imaging system.
The Architecture: We identified a consortium of VC and PE partners to form a Shenzhen-based Joint Venture with $15M in seed funding.
The Outcome: The device was fast-tracked for regulatory approval in China, and an Asian manufacturing base was established to support both regional and U.S. market demand.